Ponatinib (AP24534)

Catalog No.S1490

Molecular Weight(MW): 532.56

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

Cited by 51 Publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14329

PubMed: 25970250 ( click the link to review the publication )

Cancer Cell, 2012, 22(5):656-67

PubMed: 23153538 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Front Oncol, 2019, 9:103

PubMed: 30931252 ( click the link to review the publication )

Transl Oncol, 2019, 12(9):1221-1228

PubMed: 31276961 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Exp Dermatol, 2019, 10.1111/exd.14010

PubMed: 31338879 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2019, 46(2):126-136

PubMed: 30251267 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1405-1415

PubMed: 29695637 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):8

PubMed: 28069043 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-17-0008

PubMed: 28500237 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(6):1455-1467

PubMed: 27733071 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15219

PubMed: 29123157 ( click the link to review the publication )

Gut, 2016, 10.1136/gutjnl-2015-310382

PubMed: 26953272 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Cancer Sci, 2016, 107(2):140-8

PubMed: 26583567 ( click the link to review the publication )
Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Tumour Biol, 2016, 37(2):2365-78

PubMed: 26373734 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Leukemia, 2015, 29(5)

PubMed: 25394714 ( click the link to review the publication )

Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Toxicol Sci, 2015, 143(1):147-55

PubMed: 25304212 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120841

PubMed: 25803811 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Sci Transl Med, 2014, 6(261):261ra152

PubMed: 25378644 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Genome Biol, 2014, 15(8):428

PubMed: 25315765 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1321173111

PubMed: 24550512 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )

Structure, 2014, 22(12):1764-74

PubMed: 25465127 ( click the link to review the publication )

Oncol Rep, 2014, 31(4):1605-12

PubMed: 24481648 ( click the link to review the publication )

Thrombo Res, 2014, 135(1):155-60

PubMed: 25527332 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):54-60

PubMed: 24565842 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

Harvard University, 2014, Rachel Grace Liao

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(6):1422-32

PubMed: 23319824 ( click the link to review the publication )

Cancer Res, 2013, 73(16):5195-205

PubMed: 23786770 ( click the link to review the publication )

Neoplasia, 2013, 15(8):975-88

PubMed: 23908597 ( click the link to review the publication )
Curr Cancer Drug Targets, 2012, 12(5):505-21

PubMed: 22483156 ( click the link to review the publication )

Exp Hematol, 2012, 41(4):335-45.e3

PubMed: 23287417 ( click the link to review the publication )

Mol Genet Metab, 2010, 100(4):309-15

PubMed: 20554235 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Description

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

Targets

Abl ^[1] (Cell-free assay)	PDGFRα ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	FGFR1 ^[1] (Cell-free assay)	c-Src ^[1] (Cell-free assay)	View More
0.37 nM	1.1 nM	1.5 nM	2.2 nM	5.4 nM	View More

In vitro

AP24534 potently inhibits native Abl, Abl^T315I, and other clinically important Abl kinase domain mutants with IC50 of 0.30 nM–2 nM. AP24534 doesn't inhibit Aurora kinase family members, nor does it inhibit insulin receptor or CDK2/cyclin E. AP24534 inhibits proliferation of Ba/F3 cells expressing Bcr-Abl with IC50 of 0.5 nM, as well as Ba/F3 cells expressing a range of Bcr-Abl mutants with IC50 of 0.5 nM–36 nM. The inhibition of proliferation by AP24534 is correlated with induction of apoptosis. ^[1-2] In leukemic cell lines containing activated forms of FLT3, KIT, FGFR1, and PDGFRα receptors, AP24534 potently inhibits receptor phosphorylation and cellular proliferation with IC50 of 0.3 nM to 20 nM. In MV4-11 (FLT3-ITD(+/+)) but not RS4;11 (FLT3-ITD(–/–)) AML cells, AP24534 inhibits FLT3 signaling and induced apoptosis at less than 10 nM. AP24534 inhibits viability of primary leukemic blasts from a FLT3-ITD positive AML patient with IC50 of 4 nM but not those from patients with AML expressing native FLT3. ^[3] In Ba/F3 cells engineered to express activated FGFR1-4, AP24534 potently inhibits FGFR-mediated signaling and viability with IC50 lower than 40 nM. In cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon), and containing FGFRs dysregulated by a variety of mechanisms, AP24534 inhibits FGFR-mediated signaling with IC50 less than 40 nM and inhibits cell growth with IC50 of 7 nM–181 nM. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwMECwNFAxODN3OTFOwG0>	M1nifnNCVkeHUh?=
MV-4-11	NY\VO3h4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwMECwNFk2PiEQvF2=	MmDhV2FPT0WU
MEG-01	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvaU49KSzVyPUCuNFAxOTJ6IN88US=>	NHP3VZlUSU6JRWK=
LAMA-84	MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\meWZKSzVyPUCuNFAxOTZ3IN88US=>	Mo\uV2FPT0WU
CGTH-W-1	NITuS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLYRVR2UUN3ME2wMlAxOTZ7IN88US=>	M1;OfnNCVkeHUh?=
KASUMI-1	NG\LRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWC1WYNuUUN3ME2wMlAxOjF5IN88US=>	NELxSW1USU6JRWK=
BE-13	NYLWbZVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{[5eWlEPTB;MD6wNFI2QSEQvF2=	MmCwV2FPT0WU
CTV-1	M{LHfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwMEC1NlEh\|ryP	Ml;SV2FPT0WU
NKM-1	NIPMUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\PR29yUUN3ME2wMlAxPjV3IN88US=>	NF61XYVUSU6JRWK=
MONO-MAC-6	NYjifGZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH:yNJdKSzVyPUCuNFA5OzdizszN	M3HRPHNCVkeHUh?=
A204	NFvkZ\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7OTWM2OD1yLkCxNlE5KM7:TR?=	NY\Bb4tXW0GQR1XS
GDM-1	M1q3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1f1bGlEPTB;MD6wNVg{OyEQvF2=	Mn2wV2FPT0WU
AN3-CA	M2HRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PITWlEPTB;MD6wNVg4OyEQvF2=	Mor5V2FPT0WU
BL-70	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\RTXNKSzVyPUCuNFIyQTlizszN	NYjvfXBpW0GQR1XS
Daudi	M4XIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1O3c2lEPTB;MD6wNlU{PyEQvF2=	NHXTT5lUSU6JRWK=
KU812	MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwMEK4OFgh\|ryP	M2PnWXNCVkeHUh?=
KG-1	NX\3[XVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTBwMEOyPVQh\|ryP	MofiV2FPT0WU
DOHH-2	M13aWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4i3U2lEPTB;MD6wOFgxOyEQvF2=	NYrSfI1kW0GQR1XS
HuO9	NGHCZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnj2TWM2OD1yLkC1OFQ5KM7:TR?=	MXvTRW5ITVJ?
EB2	M3rrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml[2TWM2OD1yLkC1OVc3KM7:TR?=	MVLTRW5ITVJ?
G-402	MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\odGlEPTB;MD6wOlM1OSEQvF2=	NFHT[4NUSU6JRWK=
SU-DHL-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnGyTWM2OD1yLkC2N\|c6KM7:TR?=	NILzeVRUSU6JRWK=
NCI-H719	NIq3OG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{Xp[mlEPTB;MD6wO\|g5QCEQvF2=	NYTNdJZIW0GQR1XS
MLMA	M1PmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMEmwOkDPxE1?	MYnTRW5ITVJ?
KM12	NY\xNnRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHOTWM2OD1yLkC5O\|M4KM7:TR?=	NYPXO3p5W0GQR1XS
SUP-T1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWn0dYU5UUN3ME2wMlA6QTh{IN88US=>	NUfuXmxiW0GQR1XS
MZ1-PC	MmjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfLTWM2OD1yLkGxN\|M3KM7:TR?=	MWnTRW5ITVJ?
MFE-296	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPucoZKSzVyPUCuNVE5OzlizszN	NWPUfJlvW0GQR1XS
ALL-PO	MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHWR5hKSzVyPUCuNVI1PDNizszN	NWfMcow2W0GQR1XS
GB-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDHTIpKSzVyPUCuNVI2OTJizszN	NFfRU2RUSU6JRWK=
SIG-M5	M{nCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLud3hiUUN3ME2wMlE{OzdizszN	NGrqWWlUSU6JRWK=
P30-OHK	NF\te2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLITWM2OD1yLkG1OlczKM7:TR?=	NXi3TIpjW0GQR1XS
NCI-H716	MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zFOGlEPTB;MD6xOlI3PiEQvF2=	Mlq1V2FPT0WU
MPP-89	MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnzTWM2OD1yLkG2PVM{KM7:TR?=	MkjhV2FPT0WU
SF126	NWHQVVVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fEbGlEPTB;MD6xO\|A3OyEQvF2=	NWTue\|I{W0GQR1XS
CTB-1	NEPC[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVj4em1KUUN3ME2wMlE4OzF4IN88US=>	MWjTRW5ITVJ?
CA46	NXzrfGI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHBNHJ{UUN3ME2wMlE4PDh7IN88US=>	MVLTRW5ITVJ?
NCI-H520	NUHZO\|BJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDwTWM2OD1yLkG3O\|MzKM7:TR?=	NEfMNpRUSU6JRWK=
CAL-85-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPtOmtKSzVyPUCuNVc6OjdizszN	M{PiOHNCVkeHUh?=
NCI-H2342	M3i5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HnfmlEPTB;MD6xPFU4PyEQvF2=	MnO4V2FPT0WU
697	NF[2PGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHiXphKSzVyPUCuNVg5PzFizszN	MUHTRW5ITVJ?
NY	NWrlN2NyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwMUmyPFch\|ryP	MWPTRW5ITVJ?
T98G	NVj2Z2ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTxbXhKSzVyPUCuNVk{OThizszN	M1nYSnNCVkeHUh?=
NCI-H1703	Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojITWM2OD1yLkG5OlE2KM7:TR?=	M2PpVXNCVkeHUh?=
NCI-H2087	Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMkC0N\|kh\|ryP	Mm\sV2FPT0WU
PF-382	Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMkC4O\|Mh\|ryP	M13HW3NCVkeHUh?=
HCT-116	M13vUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nLfGlEPTB;MD6yNVA3QSEQvF2=	MUnTRW5ITVJ?
CAKI-1	MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH60dotKSzVyPUCuNlE3PjZizszN	NXHqOHNPW0GQR1XS
CCF-STTG1	NUfs[IpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIOyd3ZKSzVyPUCuNlI1PzVizszN	NFfxOlVUSU6JRWK=
D-392MG	NGmwcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HR[mlEPTB;MD6yN\|E4PyEQvF2=	NYPqUVF4W0GQR1XS
RT-112	NU\BfJY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1f4PGlEPTB;MD6yN\|c6PSEQvF2=	NXO4NopMW0GQR1XS
MES-SA	NULQRpMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDENGZKSzVyPUCuNlQyQDdizszN	MVLTRW5ITVJ?
LC-2-ad	NEP5XplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3z2R2lEPTB;MD6yOFI3PSEQvF2=	M3;1NHNCVkeHUh?=
NOS-1	NFu5[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmj4TWM2OD1yLkK0N\|Y4KM7:TR?=	NYeyUZFGW0GQR1XS
NALM-6	MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwMkW1OFMh\|ryP	MVPTRW5ITVJ?
TE-15	MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmmyTWM2OD1yLkK2NFkyKM7:TR?=	NGO3bHdUSU6JRWK=
786-0	NVjBXnAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;HfVZKSzVyPUCuNlYzOjhizszN	M3HQb3NCVkeHUh?=
IST-MES1	M3T2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPFTWM2OD1yLkK2PFI6KM7:TR?=	MXXTRW5ITVJ?
KYSE-180	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XRXWlEPTB;MD6yOlg6OSEQvF2=	NHzZ[Y9USU6JRWK=
YT	M{DKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDqSpJKSzVyPUCuNlY6PzRizszN	NWe4[GlmW0GQR1XS
A427	M1fXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PWTGlEPTB;MD6yO\|I3PCEQvF2=	MlfCV2FPT0WU
KYSE-450	NEjEb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHPSVlKSzVyPUCuNlc{OjlizszN	MojsV2FPT0WU
HuH-7	M1j3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF:yS2dKSzVyPUCuNlc4PjNizszN	MX\TRW5ITVJ?
CAS-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTic\|AxUUN3ME2wMlI5OzB\|IN88US=>	M3r4RXNCVkeHUh?=
KURAMOCHI	NFvpeWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\NOVdKSzVyPUCuNlg1OTlizszN	M372NHNCVkeHUh?=
ACHN	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvuOnl{UUN3ME2wMlI6OzJ\|IN88US=>	MX;TRW5ITVJ?
HGC-27	NVqzfYcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37F[mlEPTB;MD6yPVM2OyEQvF2=	NXfPSZdIW0GQR1XS
A172	NF6xVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwMkm1O\|ch\|ryP	NFi1[ZhUSU6JRWK=
SNU-449	NXflN\|J[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\0XoJKSzVyPUCuNlk6PjRizszN	MWXTRW5ITVJ?
SW982	Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XVdGlEPTB;MD6yPVk4QCEQvF2=	M1;LenNCVkeHUh?=
EFO-21	MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\DfGw5UUN3ME2wMlMxPDFzIN88US=>	NUPh[4pRW0GQR1XS
NCI-H2030	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{D6OGlEPTB;MD6zNVE3PCEQvF2=	NWTFR4tWW0GQR1XS
HT-144	MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTCTWM2OD1yLkOxNlgh\|ryP	NHjmfmlUSU6JRWK=
MFE-280	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\BO\|JKSzVyPUCuN\|E1PTNizszN	M3;ZRXNCVkeHUh?=
SK-LU-1	M3zPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vvVGlEPTB;MD6zNVQ3PiEQvF2=	M3uyRnNCVkeHUh?=
NCI-H2052	M2LvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fNS2lEPTB;MD6zNVQ5PCEQvF2=	NHXBV\|FUSU6JRWK=
SK-HEP-1	Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfS[mdkUUN3ME2wMlM{OzZ6IN88US=>	MXLTRW5ITVJ?
QIMR-WIL	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vzNGlEPTB;MD6zN\|QzPCEQvF2=	MVrTRW5ITVJ?
A2780	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1exc2lEPTB;MD6zOFMxPCEQvF2=	MYDTRW5ITVJ?
ACN	NGrMO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkj1TWM2OD1yLkO0PFc{KM7:TR?=	NFvXbZpUSU6JRWK=
BxPC-3	MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoK3TWM2OD1yLkO0PVg6KM7:TR?=	M{HWenNCVkeHUh?=
BCPAP	NV\aWHFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TYTWlEPTB;MD6zOlAxOSEQvF2=	M4DJUnNCVkeHUh?=
HOP-62	M3TDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoeyTWM2OD1yLkO2NVA3KM7:TR?=	Mn\0V2FPT0WU
SW1710	NFHjeGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTIS5RKSzVyPUCuN\|Y1PTVizszN	MoPWV2FPT0WU
OPM-2	MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlj6TWM2OD1yLkO2OFc{KM7:TR?=	NULqfmluW0GQR1XS
DBTRG-05MG	M37VU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnqwTWM2OD1yLkO4NFU1KM7:TR?=	NVnxdmp6W0GQR1XS
SK-MEL-24	NV61VHNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwM{m3PVEh\|ryP	Mn3OV2FPT0WU
8305C	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTBwM{m3PVMh\|ryP	M1zUc3NCVkeHUh?=
OVCAR-4	NX\sPJp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjKbWRKSzVyPUCuOFE2QDZizszN	MWTTRW5ITVJ?
HLE	M3qwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2r1bGlEPTB;MD60NVg3KM7:TR?=	MYrTRW5ITVJ?
NCI-H747	NW[4eJFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrZTFF1UUN3ME2wMlQzOTN5IN88US=>	M1Xw[XNCVkeHUh?=
SW780	MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILmdZFKSzVyPUCuOFI{PDZizszN	NVvNV5lwW0GQR1XS
KYSE-150	NUnS[mhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkCyTWM2OD1yLkSyOFE2KM7:TR?=	M4DOPHNCVkeHUh?=
H4	NYXx[HhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LsV2lEPTB;MD60NlQ2OSEQvF2=	NF;QOphUSU6JRWK=
SW1088	MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrpTWM2OD1yLkS0N\|kh\|ryP	MXnTRW5ITVJ?
SF268	NGHoOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjGdmxoUUN3ME2wMlQ1QDZizszN	NF60T49USU6JRWK=
RT4	NG\2VXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPVTWM2OD1yLkS1NVEyKM7:TR?=	NEWwbnpUSU6JRWK=
NCI-H522	NF3ZfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwNEWyO{DPxE1?	MkDQV2FPT0WU
LCLC-97TM1	NHrUOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwNE[xPVUh\|ryP	MWHTRW5ITVJ?
CAL-39	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwNE[1NVkh\|ryP	MmnBV2FPT0WU
CAL-120	MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwNEe2OFMh\|ryP	MUHTRW5ITVJ?
ESS-1	NGTyXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvETWM2OD1yLkS3PFIyKM7:TR?=	MW\TRW5ITVJ?
KARPAS-45	NXfVNnBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PaemlEPTB;MD60PFk{OyEQvF2=	NXzyRnJ1W0GQR1XS
DU-4475	NX\zTnh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwNEm1NVEh\|ryP	M{i5VHNCVkeHUh?=
VMRC-RCZ	MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrUTWM2OD1yLkS5PVA1KM7:TR?=	MknjV2FPT0WU
HOS	MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjITWM2OD1yLkWwN\|Y2KM7:TR?=	MX3TRW5ITVJ?
MOLT-16	NHXtSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TBeGlEPTB;MD61NVgxQCEQvF2=	NF;vdmFUSU6JRWK=
RPMI-6666	NXXKOHBLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDQeWxKSzVyPUCuOVIyOzVizszN	M1;HenNCVkeHUh?=
K052	NEnKSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwNUKxOEDPxE1?	NFm4NVJUSU6JRWK=
EHEB	M4DTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH2wZ41KSzVyPUCuOVIyQDJizszN	MoTtV2FPT0WU
MFH-ino	MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3pTXk5UUN3ME2wMlUzOzVzIN88US=>	NHi1UZVUSU6JRWK=
A4-Fuk	NVfSOHZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwNUK1Nlgh\|ryP	MoXJV2FPT0WU
SW1417	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XF[mlEPTB;MD61Nlc5OSEQvF2=	NXjtTHNHW0GQR1XS
DoTc2-4510	M1vuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;hR2lEPTB;MD61OFk2QCEQvF2=	MUXTRW5ITVJ?
TE-12	NV\FXmdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrTTWM2OD1yLkW1O\|M2KM7:TR?=	Mo[5V2FPT0WU
8-MG-BA	MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vrNWlEPTB;MD61OlA2PiEQvF2=	NGDRfVBUSU6JRWK=
ECC12	M4PYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTBwNU[1OVgh\|ryP	MkPwV2FPT0WU
CHL-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPkS2RDUUN3ME2wMlU4PDZ\|IN88US=>	M3zvZXNCVkeHUh?=
LCLC-103H	MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7hT5VKSzVyPUCuOVg{PDRizszN	NVKxbJJ[W0GQR1XS
OS-RC-2	MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;yWphKSzVyPUCuOVg{PzlizszN	MlT2V2FPT0WU
RO82-W-1	NIL6S2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwNUm2NVUh\|ryP	NXzte2ZqW0GQR1XS
A3-KAW	NEnRPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwNkG0Olch\|ryP	NVvjVmFGW0GQR1XS
NCCIT	Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXDZnFrUUN3ME2wMlYyPzF3IN88US=>	MlHvV2FPT0WU
IST-SL2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\jR4FHUUN3ME2wMlYzPTJ{IN88US=>	MonKV2FPT0WU
GI-ME-N	NYDteGZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vSTWlEPTB;MD62N\|A3QSEQvF2=	MnPSV2FPT0WU
ES6	M1jMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzudGZKSzVyPUCuOlMzQTVizszN	NGnLS3lUSU6JRWK=
BL-41	MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwNkOzOVIh\|ryP	MUPTRW5ITVJ?
Ca-Ski	MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\XTmtKSzVyPUCuOlQ5OSEQvF2=	NUH3VHByW0GQR1XS
HOP-92	NF7OcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwNkW2O\|Ih\|ryP	MVjTRW5ITVJ?
SK-LMS-1	M4XucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPrfIozUUN3ME2wMlY3PDdizszN	MV3TRW5ITVJ?
EW-13	MkXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3i0O2lEPTB;MD62Olc4QSEQvF2=	NEXVTWhUSU6JRWK=
647-V	MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPDT41mUUN3ME2wMlY5OTR6IN88US=>	NYfP[XdGW0GQR1XS
JiyoyeP-2003	NVjwXGtzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwNkm3N\|gh\|ryP	MoXKV2FPT0WU
WSU-NHL	M1n5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnCVWpLUUN3ME2wMlcxQDh5IN88US=>	NEHrZYdUSU6JRWK=
U-698-M	NH3SfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwN{GwOlMh\|ryP	M3zOVnNCVkeHUh?=
HC-1	M37XeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnqwTWM2OD1yLkeyOFA2KM7:TR?=	MYnTRW5ITVJ?
8505C	Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjDclVKSzVyPUCuO\|I4PDFizszN	MmXMV2FPT0WU
HUTU-80	Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1H1V2lEPTB;MD63N\|M1QSEQvF2=	Mmj6V2FPT0WU
LB1047-RCC	M{PPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjvSFdKSzVyPUCuO\|M2OzhizszN	NWrqeJJlW0GQR1XS
GAMG	MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LJT2lEPTB;MD63N\|Y2OyEQvF2=	M1P4NHNCVkeHUh?=
CAL-12T	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTYVoo{UUN3ME2wMlc{QDd5IN88US=>	NUDGdo5RW0GQR1XS
NCI-SNU-1	NYDMOmRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwN{eyO\|gh\|ryP	NVrESZdyW0GQR1XS
HTC-C3	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfF[Zp7UUN3ME2wMlc4PDVzIN88US=>	NFLvNHZUSU6JRWK=
HPAF-II	M1\6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGf5OVZKSzVyPUCuO\|c2ODFizszN	M4Ty[3NCVkeHUh?=
KGN	M4\zOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDxNGJKSzVyPUCuO\|gxQDFizszN	MmjYV2FPT0WU
EFO-27	MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4j0fWlEPTB;MD63PFc{OyEQvF2=	MlG2V2FPT0WU
MEL-HO	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrCXHdKSzVyPUCuO\|k1PDlizszN	MUfTRW5ITVJ?
KYSE-270	NIizd\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwOEC1Nlkh\|ryP	MkHUV2FPT0WU
NCI-H1755	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwOEC3NVQh\|ryP	M{PMZXNCVkeHUh?=
MFM-223	NY\6cJJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LlXWlEPTB;MD64NVQxPyEQvF2=	M1LqV3NCVkeHUh?=
G-361	NEXIeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofrTWM2OD1yLkixPFk4KM7:TR?=	MmPDV2FPT0WU
ETK-1	NEDuTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;MTWM2OD1yLkiyOFQyKM7:TR?=	NWC5[41XW0GQR1XS
LU-99A	M4PMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLTTWM2OD1yLki0O\|AyKM7:TR?=	MYfTRW5ITVJ?
IST-MEL1	NHu3WYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwOEW3N\|Ih\|ryP	NFXtNlNUSU6JRWK=
L-540	MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrTe\|ZZUUN3ME2wMlg2QDBzIN88US=>	MmL3V2FPT0WU
U-2-OS	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwOEW4OFYh\|ryP	MkLxV2FPT0WU
HT-1376	M4nW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwOE[wOVEh\|ryP	MkPBV2FPT0WU
COLO-680N	NEnNS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MomyTWM2OD1yLki3PVM{KM7:TR?=	NX3BOoRpW0GQR1XS
NCI-H1581	MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwOEmyPVch\|ryP	NFn5SY1USU6JRWK=
HuCCT1	MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDKZ2lKSzVyPUCuPFk2PDhizszN	M4nZVXNCVkeHUh?=
BB30-HNC	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLWVXhKSzVyPUCuPVI1PjlizszN	NVO4V2tiW0GQR1XS
NCI-H2347	M3rkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1izOmlEPTB;MD65N\|I6OiEQvF2=	MYTTRW5ITVJ?
G-401	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHvZXhoUUN3ME2wMlk{Pjl3IN88US=>	M1rSSXNCVkeHUh?=
NCI-H358	M130[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXv4N412UUN3ME2wMlk2ODF2IN88US=>	NVrhdFI6W0GQR1XS
HCC1395	M1jCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwOUW0OlEh\|ryP	NEW4fGFUSU6JRWK=
J82	NXPNNJFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwOUW1OFMh\|ryP	M1rwU3NCVkeHUh?=
KE-37	M{Xmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TxfWlEPTB;MD65OlM5PyEQvF2=	M4T0eXNCVkeHUh?=
NOMO-1	NYfyemlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3XTGlPUUN3ME2wMlk3PTZ2IN88US=>	NFTWZoJUSU6JRWK=
ML-2	NGHRNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXntU5pNUUN3ME2wMlk6PzVizszN	MkXkV2FPT0WU
SW872	NGjrOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHH1S4ZKSzVyPUCuPVk4PzVizszN	NV;rTWh6W0GQR1XS
KYSE-520	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrCbowzUUN3ME2xMlAxPDl2IN88US=>	NYfOUlVFW0GQR1XS
HL-60	M4PCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXmycGZOUUN3ME2xMlAxQTdizszN	MXTTRW5ITVJ?
HDLM-2	MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HOZWlEPTB;MT6wNVI2OiEQvF2=	MXfTRW5ITVJ?
MIA-PaCa-2	M4naNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjm[GxKSzVyPUGuNFE{PzVizszN	MkKyV2FPT0WU
TCCSUP	NYW4WHlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTyN5I{UUN3ME2xMlAyPzN{IN88US=>	MYDTRW5ITVJ?
SH-4	NWPscXRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HaS2lEPTB;MT6wNlI1PCEQvF2=	MWrTRW5ITVJ?
MG-63	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTFwMEK2NVYh\|ryP	MlXSV2FPT0WU
NB6	NYj2UphLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDETWM2OD1zLkCzNVA6KM7:TR?=	M{XSenNCVkeHUh?=
CAL-54	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH[5bFBKSzVyPUGuNFM6PTlizszN	MUXTRW5ITVJ?
DU-145	NXPx[IR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{i3TWlEPTB;MT6wPFA4OyEQvF2=	M1vVfnNCVkeHUh?=
HCE-4	MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjueVd3UUN3ME2xMlA6Ojh4IN88US=>	MlTPV2FPT0WU
U-266	NFfRRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTFwMEm2N\|Mh\|ryP	MknBV2FPT0WU
HT-1197	MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vUe2lEPTB;MT6xNVQ{QCEQvF2=	NYXJ[pliW0GQR1XS
EW-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTOTHBKSzVyPUGuNVQyOjhizszN	NFvsfpJUSU6JRWK=
MHH-NB-11	M4DrV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TGemlEPTB;MT6xOVM3QCEQvF2=	NX;mUGI{W0GQR1XS
NCI-H2405	M{DS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrvV29tUUN3ME2xMlE3OTZizszN	NVi4Nop6W0GQR1XS
COLO-668	NX3aUoE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTFwMU[0PUDPxE1?	M4nNTHNCVkeHUh?=
IMR-5	NFywS2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrWT3R4UUN3ME2xMlE3QTN4IN88US=>	MkP5V2FPT0WU
ARH-77	MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4POUGlEPTB;MT6yNlkzPCEQvF2=	NIf3VItUSU6JRWK=
BHT-101	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7ibIF[UUN3ME2xMlI{PDlizszN	NWLmTHVJW0GQR1XS
SCC-25	NXmyeHMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrnTWM2OD1zLkKzOVM3KM7:TR?=	M3[wR3NCVkeHUh?=
NTERA-S-cl-D1	MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjlOGdKSzVyPUGuNlQ{PDZizszN	NHj6eFBUSU6JRWK=
MKN28	MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XXcGlEPTB;MT6yOVY{PiEQvF2=	MVPTRW5ITVJ?
KS-1	NEPoZ\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTFwMkiyOlkh\|ryP	M4rpeXNCVkeHUh?=
NCI-H1734	NEnFOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrZfoNVUUN3ME2xMlI5QTF\|IN88US=>	NWHS[ZdnW0GQR1XS
ES7	M4nWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfOTWM2OD1zLkK5OVQzKM7:TR?=	NWrGfIdRW0GQR1XS
NCI-H838	M3Hxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlW0TWM2OD1zLkOwOlE2KM7:TR?=	MUjTRW5ITVJ?
HEC-1	NIPjU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTFwM{O3OVUh\|ryP	M3:2R3NCVkeHUh?=
ME-180	Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\NTWM2OD1zLkO3PVk{KM7:TR?=	Mnm3V2FPT0WU
MMAC-SF	NEi3VnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInGSmhKSzVyPUGuN\|k2QTVizszN	NXn5c\|ZkW0GQR1XS
IA-LM	NIfOPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVq0bXZLUUN3ME2xMlQxQTF2IN88US=>	M1j5Z3NCVkeHUh?=
MN-60	NXXoOXg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTFwNEOxNVQh\|ryP	NVLaNYo{W0GQR1XS
SIMA	M2rKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETjd2hKSzVyPUGuOFg3QDdizszN	NULaVoFiW0GQR1XS
NCI-H1770	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTFwNUKwOVQh\|ryP	NXjrO3ZHW0GQR1XS
ONS-76	MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTFwNUKzNVEh\|ryP	M33tXXNCVkeHUh?=
LB771-HNC	NUHIU2dmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTFwNUO5NFYh\|ryP	MlnoV2FPT0WU
SW48	NYr4UWhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXyTWM2OD1zLkW0NlQ{KM7:TR?=	NEDEfoRUSU6JRWK=
KYSE-140	NFH6Z2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2exVmlEPTB;MT61OVc1OSEQvF2=	MYHTRW5ITVJ?
SW626	NWDUZWxbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTFwNUixOkDPxE1?	MofIV2FPT0WU
MC-CAR	NGCzNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\0SnR4UUN3ME2xMlU5PjZ\|IN88US=>	NYf0fZJvW0GQR1XS
D-336MG	NGHSbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLjTWM2OD1zLk[yPVQh\|ryP	MljVV2FPT0WU
SK-MEL-3	M{PmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoG1TWM2OD1zLk[zPVAzKM7:TR?=	NXvDWXNkW0GQR1XS
MHH-PREB-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTFwNkS0O\|Mh\|ryP	MkfOV2FPT0WU
Calu-1	NEniR2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjSb3pZUUN3ME2xMlY2Ozh4IN88US=>	MX\TRW5ITVJ?
HCC1806	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTFwNk[2NVEh\|ryP	NH\TcWhUSU6JRWK=
A101D	M13oTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnGTWM2OD1zLk[2O\|gyKM7:TR?=	NWPYTZdtW0GQR1XS
A704	NFLTO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnGZ3ZKSzVyPUGuOlg{OTFizszN	M1fvUHNCVkeHUh?=
LB831-BLC	NG\t[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HQU2lEPTB;MT62PVg2PCEQvF2=	M2jzW3NCVkeHUh?=
RL95-2	MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTFwN{G0OlMh\|ryP	MYDTRW5ITVJ?
RPMI-2650	Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfobItGUUN3ME2xMlczPzF7IN88US=>	M3PXXXNCVkeHUh?=
NH-12	NYO1dXRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPQTWM2OD1zLkezOFI4KM7:TR?=	MULTRW5ITVJ?
AGS	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTFwN{[zOVgh\|ryP	MoPUV2FPT0WU
NEC8	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTFwN{i5PVUh\|ryP	NGTaS2pUSU6JRWK=
NCI-H2009	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE[xSopKSzVyPUGuO\|k4OjFizszN	NYC5Sms2W0GQR1XS
A498	NIfibWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVL0dHpNUUN3ME2xMlgyOjh{IN88US=>	M{LCb3NCVkeHUh?=
NCI-H810	NWS5TJd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPiTWM2OD1zLkixOlA3KM7:TR?=	NITjcHhUSU6JRWK=
SK-NEP-1	MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4G5UmlEPTB;MT64N\|c3PyEQvF2=	MmHIV2FPT0WU
D-542MG	M{TEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEm5W3dKSzVyPUGuPFU5PTFizszN	MUPTRW5ITVJ?
KNS-42	M2PROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPudJE1UUN3ME2xMlg3OjZ4IN88US=>	NITMUVRUSU6JRWK=
NCI-H2452	NYLaT\|VnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWG2XWpTUUN3ME2xMlg6ODd2IN88US=>	Mnz5V2FPT0WU
SK-MEL-2	NWLLfYU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPoTWM2OD1zLkmwNlcyKM7:TR?=	MYjTRW5ITVJ?
OVCAR-5	Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIH4WW9KSzVyPUGuPVA3PzVizszN	NYmweHVzW0GQR1XS
SNG-M	NWLr[XdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPrW3ZKSzVyPUGuPVU5PThizszN	NYXQU5ZFW0GQR1XS
A673	NUnh[\|NjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTFwOUe1NVYh\|ryP	NGHt[5BUSU6JRWK=
L-428	NHflPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrHbGlKSzVyPUGuPVkyPzlizszN	NV\p[nJOW0GQR1XS
KM-H2	Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TEWmlEPTB;Mj6wNVA6KM7:TR?=	MnvnV2FPT0WU
MC-IXC	NFjEd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTJwMEKyO\|Mh\|ryP	NUP5d4t5W0GQR1XS
COLO-678	M3m4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn:yTWM2OD1{LkC0NlA4KM7:TR?=	M4fPWnNCVkeHUh?=
MEL-JUSO	NYPQUoppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTJwMEe4OVEh\|ryP	NEPvNlRUSU6JRWK=
HCC38	Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4C0T2lEPTB;Mj6wPFQ{OyEQvF2=	NFTaZ5lUSU6JRWK=
UACC-62	MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2O1TGlEPTB;Mj6wPFg2PSEQvF2=	NEjofnpUSU6JRWK=
OAW-42	Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7jc4FKSzVyPUKuNFk4OTFizszN	M1\qfXNCVkeHUh?=
LB996-RCC	NVXtbo45T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HOR2lEPTB;Mj6xN\|gyPyEQvF2=	NWnSTWpsW0GQR1XS
COR-L105	NWjofpBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4W5O2lEPTB;Mj6xOlM4OyEQvF2=	M1S0[3NCVkeHUh?=
RCC10RGB	M{jzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTJwMUi1O\|Yh\|ryP	MX\TRW5ITVJ?
A431	NYnN[3lQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vQZWlEPTB;Mj6xPVAyQSEQvF2=	MXnTRW5ITVJ?
NCI-H292	NUfscJZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTJwMkO5OVEh\|ryP	M2\IWHNCVkeHUh?=
SK-UT-1	NHK0XphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfDWpBbUUN3ME2yMlM{OTh2IN88US=>	MnX6V2FPT0WU
PANC-08-13	NXjVUo9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\1TWM2OD1{LkOzNlM2KM7:TR?=	NIfYTVBUSU6JRWK=
ST486	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjxO3pKSzVyPUKuOFExPDhizszN	M4\WRnNCVkeHUh?=
SJSA-1	NGHxZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLtcpRKSzVyPUKuOFEzPzFizszN	MWnTRW5ITVJ?
RKO	MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3u0cGlEPTB;Mj60NlAzQSEQvF2=	NHXpOWVUSU6JRWK=
NCI-H1793	M1PRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jvR2lEPTB;Mj60OFAzQSEQvF2=	MXnTRW5ITVJ?
639-V	M4\6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3va[WlEPTB;Mj60OVM5OiEQvF2=	NV3weI1IW0GQR1XS
ES3	NXmzUWhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DtRmlEPTB;Mj60PVc{PyEQvF2=	NInBNXNUSU6JRWK=
NCI-H1792	NEeycnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTuTWM2OD1{LkW2PFI3KM7:TR?=	NGK4[VFUSU6JRWK=
NCI-H1651	M36ySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTJwNUiyNUDPxE1?	M2fz[HNCVkeHUh?=
SN12C	Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTJwNUi0PFch\|ryP	NVHObGdrW0GQR1XS
COLO-679	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XMOGlEPTB;Mj61PFYxPSEQvF2=	MVvTRW5ITVJ?
U-118-MG	NVz5fJBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnr1TWM2OD1{LkW4PFczKM7:TR?=	MX7TRW5ITVJ?
Ramos-2G6-4C10	MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zOWGlEPTB;Mj62OFgxPyEQvF2=	MoDqV2FPT0WU
HCT-15	NX3vWI83T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlH1TWM2OD1{Lk[4O\|kzKM7:TR?=	NIjKPXZUSU6JRWK=
MDA-MB-157	NXXFRnM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTJwN{C3OFch\|ryP	M370R3NCVkeHUh?=
K5	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nkXmlEPTB;Mj63NVg1PSEQvF2=	MWjTRW5ITVJ?
MKN45	MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXzZXhKSzVyPUKuO\|M{PjZizszN	NEHicXNUSU6JRWK=
DMS-273	MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjPRoFtUUN3ME2yMlc2PjN{IN88US=>	MmLpV2FPT0WU
C8166	MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHaUJdKSzVyPUKuO\|g2OTNizszN	NF\HfplUSU6JRWK=
Calu-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXy3b4NXUUN3ME2yMlc5QTZ7IN88US=>	NUXX[Yx5W0GQR1XS
SNB75	NFrjNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDMTWM2OD1{Lki4OVM2KM7:TR?=	M13TRXNCVkeHUh?=
BFTC-905	M1nEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzQPHBpUUN3ME2yMlkxOTlzIN88US=>	Ml\DV2FPT0WU
C-4-II	NGjGZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUi1Tmc{UUN3ME2yMlkyOzV\|IN88US=>	M4P4TnNCVkeHUh?=
MS-1	NFL3SIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XvNGlEPTB;Mj65Olc3QSEQvF2=	M1z0THNCVkeHUh?=
A375	MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjhOYhGUUN3ME2zMlA5OTh2IN88US=>	M{PGb3NCVkeHUh?=
KYSE-70	NHHsbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPjXWlKSzVyPUOuNFg5QDJizszN	MULTRW5ITVJ?
KYSE-510	NX;O[HlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTNwMUC5PVUh\|ryP	MoD0V2FPT0WU
LN-405	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\GTWM2OD1\|LkGzOVE5KM7:TR?=	MWDTRW5ITVJ?
BOKU	MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jFemlEPTB;Mz6xOFI2PiEQvF2=	NXS5OVdyW0GQR1XS
TE-10	NF;ReYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTNwMUezOlIh\|ryP	M37lNHNCVkeHUh?=
MKN1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXG0elJlUUN3ME2zMlE5PDh\|IN88US=>	MW\TRW5ITVJ?
M059J	NYnwOY9ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXjfodsUUN3ME2zMlIxOTd\|IN88US=>	MUHTRW5ITVJ?
GOTO	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTNwMkKwN\|kh\|ryP	M3rGXnNCVkeHUh?=
DK-MG	M3fRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7S[pUzUUN3ME2zMlI2QTd4IN88US=>	NHjwNm1USU6JRWK=
NCI-H727	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\WTWM2OD1\|LkK2OVgh\|ryP	MWfTRW5ITVJ?
NB12	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHDTWM2OD1\|LkOzNlI1KM7:TR?=	MnTZV2FPT0WU
DOK	Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGntR2lKSzVyPUOuN\|YyQDZizszN	NWq2VGZWW0GQR1XS
KYSE-410	NHG4[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;aTWM2OD1\|LkO2Nlg4KM7:TR?=	NH\YR4RUSU6JRWK=
AM-38	M1jOd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGH5e2ZKSzVyPUOuN\|gxPTFizszN	M3HhTXNCVkeHUh?=
GR-ST	NWLrcWt7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DJNGlEPTB;Mz60OVc{OiEQvF2=	M{n3RnNCVkeHUh?=
D-247MG	M{fvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn76TWM2OD1\|LkS4NlY{KM7:TR?=	NXTmSGpCW0GQR1XS
TE-8	NGP1OGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37XRWlEPTB;Mz60PVM{OyEQvF2=	MX;TRW5ITVJ?
LS-411N	MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1uzOmlEPTB;Mz60PVY6OiEQvF2=	M3LHUnNCVkeHUh?=
SK-MES-1	M2nUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFn4VldKSzVyPUOuOVY1OzNizszN	NF\wOnlUSU6JRWK=
SF295	NIDEZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHadZFKSzVyPUOuOlE2PTJizszN	MXHTRW5ITVJ?
SK-MEL-30	M{Phdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvVcolKSzVyPUOuOlU6OjFizszN	MVzTRW5ITVJ?
LB2241-RCC	NXPzN4xGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzTSlVKSzVyPUOuOlYzPiEQvF2=	M4DH[HNCVkeHUh?=
PC-14	NFfGb2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;ISWlEPTB;Mz62OlQ{PyEQvF2=	NVP4e5hlW0GQR1XS
EW-7	NEKz[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXXdHpKSzVyPUOuOlc3QTNizszN	NWDMWGZ[W0GQR1XS
NMC-G1	M{TXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnvS4YzUUN3ME2zMlcyQDN5IN88US=>	MX3TRW5ITVJ?
TE-441-T	NHfj[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoSwTWM2OD1\|LkezNFI5KM7:TR?=	NGHhO\|dUSU6JRWK=
NCI-H1618	Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTNwOEG4O\|Uh\|ryP	M2nZO3NCVkeHUh?=
PANC-03-27	NWnlSI42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LOWGlEPTB;Mz64NVkyPiEQvF2=	NHfJW3NUSU6JRWK=
NCI-H2228	M1Ph[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnL2TWM2OD1\|LkizNVI3KM7:TR?=	MmPGV2FPT0WU
CAPAN-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rleGlEPTB;Mz64O\|AxQSEQvF2=	M1;IZ3NCVkeHUh?=
KLE	NHHVPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTNwOUC2O{DPxE1?	M1H6TnNCVkeHUh?=
Becker	M2r4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTNwOUK4OFkh\|ryP	MXPTRW5ITVJ?
SK-PN-DW	M1PHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTyTWM2OD12LkC3PVc1KM7:TR?=	MV3TRW5ITVJ?
Hs-578-T	Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M36wRWlEPTB;ND6wPFMxPiEQvF2=	NWKxfpZMW0GQR1XS
RS4-11	NUDhfHkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnKxTWM2OD12LkGxNlU2KM7:TR?=	NYfDOppjW0GQR1XS
D-502MG	NFizUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXntfJFJUUN3ME20MlE3QTl5IN88US=>	M2e3dXNCVkeHUh?=
GI-1	NWO5R4t5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfjdodLUUN3ME20MlI5Ojl7IN88US=>	NHO2SFZUSU6JRWK=
NCI-H209	M1qzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;2TWM2OD12LkOzO\|gh\|ryP	Ml;MV2FPT0WU
SK-OV-3	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;rUGlEPTB;ND60PFE1QSEQvF2=	NYfIOo5mW0GQR1XS
LOUCY	M2LRWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfSPJpKSzVyPUSuOFg1OzJizszN	M125dHNCVkeHUh?=
NCI-H69	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnIRnZsUUN3ME20MlUyPzl\|IN88US=>	NIm5bZZUSU6JRWK=
SCC-9	MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDQWG13UUN3ME20MlU{OTd{IN88US=>	MYTTRW5ITVJ?
NCI-H526	Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVy5R2F1UUN3ME20MlU6Ojl\|IN88US=>	MmX3V2FPT0WU
NCI-H2170	MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEP4U\|BKSzVyPUSuOlY4PzFizszN	MUfTRW5ITVJ?
SR	Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\mSlhTUUN3ME20MlcxODR6IN88US=>	MYPTRW5ITVJ?
CMK	NX;RdWJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlS1TWM2OD12LkeyNVAyKM7:TR?=	NUTmVoh{W0GQR1XS
COLO-829	M1vuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlz6TWM2OD12Lke3NFQ{KM7:TR?=	MoTvV2FPT0WU
HuO-3N1	NVuyOmg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGKyZmtKSzVyPUSuPFMzQDFizszN	NYnwNnM3W0GQR1XS
5637	NGfIR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1u5VmlEPTB;ND65NFQ5PyEQvF2=	M1fPTXNCVkeHUh?=
A253	NVOyfohCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3[2VmlEPTB;ND65O\|cxQCEQvF2=	M4ezenNCVkeHUh?=
NB10	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPqTWM2OD13LkC3OFk4KM7:TR?=	MkC2V2FPT0WU
SF539	Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPzdW5ZUUN3ME21MlA6QTV7IN88US=>	Mk\OV2FPT0WU
HAL-01	M4TLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTRTWM2OD13LkG0OlQ2KM7:TR?=	MVnTRW5ITVJ?
MHH-ES-1	NGLmbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFW2RpNKSzVyPUWuNVY6OjVizszN	NVOwXVJRW0GQR1XS
DEL	NVux[5YzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnCV4hKSzVyPUWuNlc2QDJizszN	Mk\GV2FPT0WU
NCI-H1299	M{\iPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\aZ41uUUN3ME21MlM2ODB5IN88US=>	MUjTRW5ITVJ?
ChaGo-K-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\CR2duUUN3ME21MlM2OTB5IN88US=>	NGnxb3JUSU6JRWK=
HMV-II	NF;MToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUi3fpRUUUN3ME21MlM6PDNizszN	NUfm[FBGW0GQR1XS
NB69	M2LjdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfhfIRNUUN3ME21MlM6PjNzIN88US=>	NVTScm5qW0GQR1XS
NCI-H1882	M2H1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHlTWM2OD13LkSzN\|Y1KM7:TR?=	MU\TRW5ITVJ?
SNU-475	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDHNI5KSzVyPUWuOFcyPzFizszN	M17kZ3NCVkeHUh?=
RXF393	NX3Tfm5uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTVwNEi0PVQh\|ryP	NVLMUI1QW0GQR1XS
CAL-51	M4\PPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\5U\|ZKSzVyPUWuOlI5PTNizszN	MXHTRW5ITVJ?
SW1573	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NICzRXhKSzVyPUWuOlM2OzRizszN	NEW1T3lUSU6JRWK=
GCT	M1ntU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nONmlEPTB;NT63OVkzQSEQvF2=	NIHwUWVUSU6JRWK=
COR-L88	MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTVwN{[4OFYh\|ryP	MnzwV2FPT0WU
MDA-MB-134-VI	Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTVwOEe1N\|Yh\|ryP	MWLTRW5ITVJ?
NB5	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIGw[5hKSzVyPUWuPVI1PCEQvF2=	Mme2V2FPT0WU
GMS-10	NHfHe4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvhTWM2OD13Lkm2PFYyKM7:TR?=	M1zmTXNCVkeHUh?=
CHP-212	MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF6xfY5KSzVyPU[uOFgzPjdizszN	NVrP[FBCW0GQR1XS
TE-11	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnMTXhKSzVyPU[uOVUyQDJizszN	MmGxV2FPT0WU
SW962	NXflN5NJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;Je2lEPTB;Nj62OVc4PCEQvF2=	NVz2WlVGW0GQR1XS
MZ2-MEL	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH25TGVKSzVyPU[uPFIxOTFizszN	NULYWFlJW0GQR1XS
C-33-A	NV3iWXJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17lbmlEPTB;Nj65NVY5QCEQvF2=	NV;aVoRNW0GQR1XS
IGR-1	Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fz[GlEPTB;Nj65O\|gzPiEQvF2=	M2XaTnNCVkeHUh?=
MOLT-4	MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIX0fGtKSzVyPUeuNVU1ODZizszN	MmLUV2FPT0WU
NCI-H1650	MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zEemlEPTB;Nz6yO\|A1PiEQvF2=	MmLTV2FPT0WU
AsPC-1	NV;I[3NZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\oVoliUUN3ME23MlI5PjB3IN88US=>	NEHXblBUSU6JRWK=
SNU-C2B	MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nleGlEPTB;Nz6yPVU4OSEQvF2=	NHLp[lJUSU6JRWK=
MKN7	MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnK0TWM2OD15LkO3NlM2KM7:TR?=	NH\keWhUSU6JRWK=
SW620	NWrD[lBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7SbFBKSzVyPUeuN\|gzODVizszN	MXrTRW5ITVJ?
SK-MEL-28	NIfZPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfVTWM2OD15LkSwO\|k5KM7:TR?=	NGnlUmdUSU6JRWK=
TE-6	M{HCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrMZWExUUN3ME23MlQ1QTB6IN88US=>	NYDWR5FGW0GQR1XS
D-263MG	M{nxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rhRmlEPTB;Nz60OVc3OiEQvF2=	NEmweppUSU6JRWK=
NCI-H1355	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jiXWlEPTB;Nz63O\|AzQSEQvF2=	MVTTRW5ITVJ?
DSH1	MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzzNHdUUUN3ME23Mlc6PzZ{IN88US=>	M4C4XXNCVkeHUh?=
NCI-H460	NEWwPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRThwMEC2PVQh\|ryP	Mn7NV2FPT0WU
NCI-H1563	NVfteWFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fQNGlEPTB;OD6wO\|UxQCEQvF2=	NIfndJRUSU6JRWK=
SW948	NW\l[WdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnX[lNxUUN3ME24MlExPzR2IN88US=>	NEPnZ3RUSU6JRWK=
LK-2	NVnWRmk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnLbXdLUUN3ME24MlEzQDN\|IN88US=>	NUHDPWNFW0GQR1XS
HT-1080	M{\MZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\FTWM2OD16LkGzNVc2KM7:TR?=	NFjIUG5USU6JRWK=
NCI-H441	NGPzfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml:zTWM2OD16LkG5N{DPxE1?	M{fwTXNCVkeHUh?=
HSC-4	NWSzc49XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGr6c4RKSzVyPUiuNlg4OiEQvF2=	NITtXFlUSU6JRWK=
LXF-289	NFvaV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDsRW03UUN3ME24MlM2QTR\|IN88US=>	MkK4V2FPT0WU
MRK-nu-1	NGL4ZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fFNGlEPTB;OD6zOlMxPCEQvF2=	NVLWfmRkW0GQR1XS
no-11	NGTS[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjCTWM2OD16LkS3NVM{KM7:TR?=	NWTGRmZ3W0GQR1XS
SNU-387	NEHIeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;aVGlEPTB;OD62N\|I1PiEQvF2=	MYXTRW5ITVJ?
Detroit562	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\4Z2lEPTB;OD63OVQ2PSEQvF2=	M{H1S3NCVkeHUh?=
SW954	M4Lq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPqTWM2OD16Lke2PFMzKM7:TR?=	MlfuV2FPT0WU
P12-ICHIKAWA	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXmOWt[UUN3ME24Mlc5QTRizszN	M17DenNCVkeHUh?=
TE-9	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDYfmt2UUN3ME24MlgyODZ{IN88US=>	NVXaOVV7W0GQR1XS
NB13	MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorsTWM2OD16LkizO\|k3KM7:TR?=	NXHTc5pMW0GQR1XS
BPH-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3W5fGlEPTB;OD64OVA5OSEQvF2=	NHfLUHZUSU6JRWK=
KMOE-2	NYDhO4xNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkO4TWM2OD16Lki3PFkzKM7:TR?=	M{HIRXNCVkeHUh?=
RPMI-8402	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnkTWM2OD16Lki5PVI3KM7:TR?=	MnTsV2FPT0WU
OVCAR-3	Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7ITWM2OD16Lkm3O\|MzKM7:TR?=	M{HMb3NCVkeHUh?=
NCI-H2196	Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\yPXJxUUN3ME24Mlk5PjB4IN88US=>	M1ezS3NCVkeHUh?=
MZ7-mel	NGPkOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFSwS5FKSzVyPUmuNFM1PiEQvF2=	MWrTRW5ITVJ?
GP5d	MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTlwME[zNVMh\|ryP	NIPENGJUSU6JRWK=
NCI-N87	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTRTWM2OD17LkS0O\|MyKM7:TR?=	MkjlV2FPT0WU
EW-16	MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3Hkb2lEPTB;OT60OFg1QCEQvF2=	Mle1V2FPT0WU
Calu-6	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYriOWdzUUN3ME25MlQ6PzB\|IN88US=>	Ml\xV2FPT0WU
LC4-1	NX7HZZhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrZTWM2OD17Lk[yOVch\|ryP	NFzqZ\|ZUSU6JRWK=
CCRF-CEM	M4npN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TJ[2lEPTB;OT62PFc3PiEQvF2=	Ml71V2FPT0WU
BC-1	NWqyXot7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\XTpV1UUN3ME25Mlc5QTlizszN	MVTTRW5ITVJ?
NCI-SNU-16	NFLqTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTlwN{m0PVUh\|ryP	Ml\uV2FPT0WU
NCI-H28	M{fCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmO5TWM2OD17Lki0PVM{KM7:TR?=	NH:5NodUSU6JRWK=
SBC-1	MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrRUZFTUUN3ME2xNE4xPzJizszN	NVvT[HM5W0GQR1XS
TUR	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTvWlNKSzVyPUGwMlE3PTdizszN	NGLlUVRUSU6JRWK=
MDA-MB-231	M1faVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PKWmlEPTB;MUCuNlEyPCEQvF2=	M37WZ3NCVkeHUh?=
C3A	MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnheHVKSzVyPUGwMlMyPzlizszN	MlvxV2FPT0WU
SW1990	Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\WPWlEPTB;MUCuN\|I5KM7:TR?=	M1vMfHNCVkeHUh?=
NCI-H1993	M4TrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PST2lEPTB;MUCuOVY6OyEQvF2=	MYXTRW5ITVJ?
SK-CO-1	NEm4[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHyNplHUUN3ME2xNE44PzdizszN	Mmn1V2FPT0WU
OAW-28	M1y5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfqcWg4UUN3ME2xNE46QDh6IN88US=>	NU\FbFZjW0GQR1XS
HN	NInne\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mly4TWM2OD1zMT6xNVMyKM7:TR?=	M{PafnNCVkeHUh?=
NCI-H1304	NFTu[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI[5dZlKSzVyPUGxMlE2PzZizszN	M1jYe3NCVkeHUh?=
Daoy	MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFv3[IJKSzVyPUGxMlQ{OzZizszN	MVXTRW5ITVJ?
VA-ES-BJ	M{m2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTFzLkexPVUh\|ryP	NGrhZlBUSU6JRWK=
MCF7	NEPjb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk[0TWM2OD1zMT64NVI3KM7:TR?=	NFW2[\|VUSU6JRWK=
VM-CUB-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGP4[4VKSzVyPUGxMlkxQTFizszN	MWnTRW5ITVJ?
IPC-298	NF36XFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nGc2lEPTB;MUGuPVM5OyEQvF2=	MV3TRW5ITVJ?
NCI-H2126	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEe5d4pKSzVyPUGyMlAzOThizszN	Ml3uV2FPT0WU
OVCAR-8	Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fLPGlEPTB;MUKuNVE1OSEQvF2=	NVmxXI9KW0GQR1XS
SJRH30	MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTF{LkKyPVkh\|ryP	NWrCcHp5W0GQR1XS
DMS-53	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFflPIRKSzVyPUGyMlI3PDlizszN	NUfIeHo4W0GQR1XS
NCI-H322M	M3rJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Llc2lEPTB;MUKuN\|M2PyEQvF2=	NHzBbXJUSU6JRWK=
RVH-421	MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXhTWM2OD1zMj60PVA1KM7:TR?=	MXvTRW5ITVJ?
Raji	MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2ixVmlEPTB;MUKuOlE1KM7:TR?=	NUTtWGpNW0GQR1XS
MDA-MB-415	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTF{Lk[0OFQh\|ryP	NVHVUpdmW0GQR1XS
EFE-184	MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXEWIZKSzVyPUGyMlcyODZizszN	NX;n[Ic6W0GQR1XS
BFTC-909	NYrZOmdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLuTWM2OD1zMj65NlQ4KM7:TR?=	NX\YdmRzW0GQR1XS
BHY	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn72TWM2OD1zMz6zN\|kh\|ryP	M2rV[nNCVkeHUh?=
YKG-1	NWm1[otNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVz3VG5mUUN3ME2xN{4{PzR7IN88US=>	NHzV[VFUSU6JRWK=
EW-3	NF;vNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPETWM2OD1zMz63NVY{KM7:TR?=	NFnxcW9USU6JRWK=
HCC1143	NYjxU2JDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHj6TGNKSzVyPUGzMlc1OzdizszN	MXrTRW5ITVJ?
REH	NXHNV5FKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTF\|Lki5PFIh\|ryP	MkHiV2FPT0WU
CESS	NYHBcZp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIO4Z21KSzVyPUGzMlk1QDlizszN	NFvMOmVUSU6JRWK=
EFM-19	NH;HZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWezNY1RUUN3ME2xOE4yOTF{IN88US=>	Mmf5V2FPT0WU
U031	NV7DR5Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGe5PVlKSzVyPUG0MlQxQDVizszN	MVfTRW5ITVJ?
ES1	M{Hae2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HhWGlEPTB;MUSuOFg2OSEQvF2=	MUHTRW5ITVJ?
HSC-3	NUG1e\|ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33WZ2lEPTB;MUSuOlIyPSEQvF2=	M2WzVnNCVkeHUh?=
LOXIMVI	M{fnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIe1SFlKSzVyPUG0MlcxPjhizszN	NFGwXYJUSU6JRWK=
A388	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DSVmlEPTB;MUSuO\|U2PiEQvF2=	M17UWXNCVkeHUh?=
KP-N-YS	NILZXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\nTWM2OD1zND63O\|Mh\|ryP	M2rLSnNCVkeHUh?=
Capan-2	M13WdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4ixemlEPTB;MUSuO\|g3KM7:TR?=	MnPVV2FPT0WU
SKG-IIIa	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITLWGNKSzVyPUG0Mlg5PjJizszN	MkC1V2FPT0WU
HEL	NFSxfGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HRbWlEPTB;MUSuPFk6PyEQvF2=	M{LuTXNCVkeHUh?=
BEN	NEXSb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{X4WmlEPTB;MUSuPVc3PiEQvF2=	NXryZm11W0GQR1XS
MC116	NGiwfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;YVmU5UUN3ME2xOU4yPTl7IN88US=>	MYHTRW5ITVJ?
IGROV-1	NVPSdmVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnuTmtKSzVyPUG1MlI{OTdizszN	NYr3Z3BGW0GQR1XS
NCI-H1648	M{jEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLiTWM2OD1zNT61N\|A2KM7:TR?=	MlrXV2FPT0WU
ABC-1	MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PMc2lEPTB;MUWuPFA{OyEQvF2=	M4HxWHNCVkeHUh?=
EW-18	M{Tjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rONWlEPTB;MUWuPVk4QSEQvF2=	NYPnU3R[W0GQR1XS
BC-3	NVLMUoFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NISxNnpKSzVyPUG2MlA2PjJizszN	Ml\zV2FPT0WU
NCI-H1437	MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTF4LkC2Olch\|ryP	MoTCV2FPT0WU
SCC-15	NWLjRYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHmTWM2OD1zNj6yPFI2KM7:TR?=	MkXuV2FPT0WU
TT	NEnQcVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUD1XJdLUUN3ME2xOk42QDh6IN88US=>	MUTTRW5ITVJ?
KINGS-1	MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTF4LkiyO\|Mh\|ryP	NGTWPYVUSU6JRWK=
C32	NV3YOFR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7oTWM2OD1zNj65O\|E4KM7:TR?=	MnPTV2FPT0WU
SBC-5	NWfjS3ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfzTWM2OD1zNz6xOFc6KM7:TR?=	MnTYV2FPT0WU
NB1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjBTWM2OD1zNz6zNVg5KM7:TR?=	Ml7kV2FPT0WU
EB-3	NHvoTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTF5LkW3OkDPxE1?	NUi5cJp[W0GQR1XS
NCI-H748	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrEXlFbUUN3ME2xO{44ODN3IN88US=>	NIm3RVBUSU6JRWK=
IST-SL1	NH;WXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{L2[mlEPTB;MUeuO\|UzPiEQvF2=	MnH5V2FPT0WU
WM-115	NWrQcHBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTF5LkiwPFUh\|ryP	NWrNcmNSW0GQR1XS
NCI-H226	M4jpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLLcGVKUUN3ME2xO{46PTR4IN88US=>	Mn3VV2FPT0WU
CAL-33	NWnKOFNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTF6LkK3PFEh\|ryP	NX2ydHg{W0GQR1XS
SCC-4	NVTFS\|QzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jnNGlEPTB;MUiuN\|IzQSEQvF2=	NEfJV3dUSU6JRWK=
RMG-I	NWH3ZXl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYO5ellGUUN3ME2xPE43QTR5IN88US=>	M13FeXNCVkeHUh?=
KOSC-2	NI\WdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTRTnlKUUN3ME2xPE44PzR4IN88US=>	M3\HfXNCVkeHUh?=
A2058	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkK5TWM2OD1zOD64NlU2KM7:TR?=	MUnTRW5ITVJ?
HCC70	M1npSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTF7LkO4PVQh\|ryP	Ml;VV2FPT0WU
C2BBe1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTF7LkSxOFgh\|ryP	NYLpboRsW0GQR1XS
NCI-H650	NInZSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDq[JBKSzVyPUG5MlU5QTlizszN	MYLTRW5ITVJ?
CAL-72	NUHFW\|BqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M335cWlEPTB;MUmuOlc{PyEQvF2=	MWTTRW5ITVJ?
L-363	MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HtZ2lEPTB;MkCuNFIyOiEQvF2=	NF;xSWNUSU6JRWK=
SNU-423	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljyTWM2OD1{MD6xNFQ{KM7:TR?=	NHTidphUSU6JRWK=
PLC-PRF-5	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTJyLkO5NFYh\|ryP	NIHifHZUSU6JRWK=
SW1463	M1TQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnniTWM2OD1{MD60OVI2KM7:TR?=	M2HZN3NCVkeHUh?=
769-P	NYTMOY1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTJyLk[3Olkh\|ryP	NULhVXBIW0GQR1XS
DMS-79	MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGq1Z49KSzVyPUKwMlg1QSEQvF2=	NIP5SopUSU6JRWK=
Saos-2	M4nZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LYSmlEPTB;MkCuPVU2PiEQvF2=	NH25UIpUSU6JRWK=
CHP-126	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnr5TWM2OD1{MT60OFYzKM7:TR?=	NEXPZVZUSU6JRWK=
SW837	NHLBOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPPWpBTUUN3ME2yNU41QTN7IN88US=>	NVXPWYd5W0GQR1XS
SHP-77	MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2Dr[2lEPTB;MkGuOlEzOiEQvF2=	M{jPNXNCVkeHUh?=
DB	NFfreHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HFUmlEPTB;MkGuOlE1OiEQvF2=	MWrTRW5ITVJ?
ES5	NUDSUnlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTJzLk[4OlQh\|ryP	NILofGFUSU6JRWK=
COR-L23	NF\5RVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrsT\|ZYUUN3ME2yNU45ODVzIN88US=>	NVK5bJFLW0GQR1XS
KU-19-19	NX24cYU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fKbGlEPTB;MkGuPFk5OiEQvF2=	NWriOohSW0GQR1XS
T84	MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTJzLkm4NVkh\|ryP	MV;TRW5ITVJ?
NCI-H630	MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYD4fotnUUN3ME2yNk42OzZ\|IN88US=>	MlHlV2FPT0WU
LU-165	NGPrRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnUU2VKSzVyPUKyMlU2PCEQvF2=	NG[zbmZUSU6JRWK=
COLO-792	NG\weZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{T1RWlEPTB;MkKuO\|EyOSEQvF2=	MojBV2FPT0WU
CAL-62	NE\Le\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTlc3NvUUN3ME2yNk44PTF5IN88US=>	Ml;JV2FPT0WU
HCE-T	NF\sPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTJ{Lki2NFYh\|ryP	NFHSWWhUSU6JRWK=
BB65-RCC	NXHTU4Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTJ\|LkCzOFQh\|ryP	M4XUdnNCVkeHUh?=
SiHa	M3nYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jJR2lEPTB;MkOuN\|k3QCEQvF2=	MnrWV2FPT0WU
NCI-H2081	MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEf3XotKSzVyPUK0MlA3PDFizszN	NV7SR2FRW0GQR1XS
U251	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLnTWM2OD1{ND6wOlY5KM7:TR?=	NWXVdo1mW0GQR1XS
LoVo	NXrRVVk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDQTWM2OD1{ND65NlgzKM7:TR?=	MlrHV2FPT0WU
GCIY	NIn6RWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFH2fodKSzVyPUK1MlI5PzdizszN	MVTTRW5ITVJ?
NUGC-3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTJ3LkOzNVYh\|ryP	M2GzWnNCVkeHUh?=
LNCaP-Clone-FGC	NITkdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTJ3LkO0PVgh\|ryP	M4LnTXNCVkeHUh?=
PA-1	MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{eyeGlEPTB;MkWuOlg{OyEQvF2=	NIqxR2RUSU6JRWK=
OE33	NEnrV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTJ3Lk[4OVMh\|ryP	MVfTRW5ITVJ?
HT-29	NIj3S4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPrSWdTUUN3ME2yOU44QDd7IN88US=>	NWTDe5R[W0GQR1XS
RCM-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\pT2FKSzVyPUK1Mlk3PTZizszN	MWDTRW5ITVJ?
NCI-H1522	M1HRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTNTWM2OD1{NT65PVEyKM7:TR?=	M3XkVXNCVkeHUh?=
LB373-MEL-D	M4DHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTJ4LkG3NFgh\|ryP	MnjmV2FPT0WU
NCI-H1436	NHPjVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\pclREUUN3ME2yOk4zPzN6IN88US=>	NFHuV41USU6JRWK=
COLO-824	NGX4UnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTJ4LkSwNFIh\|ryP	NUfWPFNQW0GQR1XS
CP50-MEL-B	M{XWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXCSoZKSzVyPUK2MlU3PzVizszN	NXywWFhkW0GQR1XS
EGI-1	NGfTdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVL4[Go5UUN3ME2yO{4zPjl6IN88US=>	MWXTRW5ITVJ?
LAN-6	NV;QcWFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jiOmlEPTB;MkeuN\|U6QCEQvF2=	MY\TRW5ITVJ?
GAK	MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nJVGlEPTB;MkeuOFIzPSEQvF2=	MWLTRW5ITVJ?
MDA-MB-175-VII	MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTJ5LkWwOVMh\|ryP	MYfTRW5ITVJ?
JVM-2	MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HKSmlEPTB;MkeuOlYzOiEQvF2=	M4jLcnNCVkeHUh?=
UACC-257	NYHYU4FrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;vOWlEPTB;MkeuOlg4QCEQvF2=	MmXjV2FPT0WU
SW1783	NYjZR\|NyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrlSIlKSzVyPUK3Mlc4QDNizszN	M3jJWXNCVkeHUh?=
HT-3	NGfiWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7IOHI4UUN3ME2yPE4zOTZ4IN88US=>	M1vSU3NCVkeHUh?=
RL	M2f2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWn5eXpbUUN3ME2yPE42QTFzIN88US=>	NXGyWXpMW0GQR1XS
TK10	MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;UTI1TUUN3ME2yPE43PTN3IN88US=>	NUfuXWdTW0GQR1XS
HT55	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1i2V2lEPTB;MkmuNFU3PSEQvF2=	M2OyZ3NCVkeHUh?=
BT-20	Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrsR5BKSzVyPUK5MlA2QDZizszN	MmPuV2FPT0WU
TGBC24TKB	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3ue3ZKSzVyPUK5MlE5OzFizszN	NF\sR3dUSU6JRWK=
HSC-2	NYXjUVNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTJ7LkOwNFEh\|ryP	MlmwV2FPT0WU
COLO-205	NGOy[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH74cpJKSzVyPUK5MlM6PDRizszN	MUjTRW5ITVJ?
GT3TKB	M1vFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTJ7Lk[4O\|ch\|ryP	M4TVVHNCVkeHUh?=
T47D	MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU[1U3dwUUN3ME2yPU45PTh{IN88US=>	NWHTeW5nW0GQR1XS
OMC-1	MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHiTWM2OD1\|MD6xPVE6KM7:TR?=	MnvVV2FPT0WU
PFSK-1	NHrSWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGGxcWZKSzVyPUOxMlI3PTlizszN	MmTtV2FPT0WU
JEG-3	NYXyXYhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTNzLkO1OlEh\|ryP	MkHxV2FPT0WU
RD	MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXe4XG9oUUN3ME2zNU42OTF3IN88US=>	M1X4T3NCVkeHUh?=
NCI-H64	Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfZWpp1UUN3ME2zNk41OTd7IN88US=>	MWHTRW5ITVJ?
DMS-114	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnj0TWM2OD1\|Mj60NVgzKM7:TR?=	NE\6SohUSU6JRWK=
NCI-H661	M4H5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HXVWlEPTB;M{KuOlUxOSEQvF2=	MYPTRW5ITVJ?
CAL-148	NI\3eVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDFTWM2OD1\|Mj62OlY2KM7:TR?=	MYLTRW5ITVJ?
HuP-T3	Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfoTWM2OD1\|Mj65N\|M5KM7:TR?=	NFqxXoxUSU6JRWK=
ES4	NHHVW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljiTWM2OD1\|Mz6xO\|A2KM7:TR?=	NXnmem5UW0GQR1XS
Ca9-22	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTN\|LkS2NFEh\|ryP	NFjDXWJUSU6JRWK=
LP-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLzS5NSUUN3ME2zOE4xQSEQvF2=	M2TLcnNCVkeHUh?=
AU565	NEjOZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXNTWM2OD1\|ND61NFY6KM7:TR?=	M33hXnNCVkeHUh?=
MDA-MB-453	M3fZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlv1TWM2OD1\|NT6xOFI3KM7:TR?=	NF32Z4xUSU6JRWK=
SNU-C1	M4T0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTN3LkG3NUDPxE1?	MlPZV2FPT0WU
SW13	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTN3LkSwO\|Yh\|ryP	NVnhXGlSW0GQR1XS
NCI-H2122	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDNR45KUUN3ME2zOU42PTl6IN88US=>	MUDTRW5ITVJ?
NCI-H1395	NF\Yco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTN3Lk[2PVEh\|ryP	M2PScnNCVkeHUh?=
J-RT3-T3-5	NXvlPWMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvtTWM2OD1\|Nj6wNlk1KM7:TR?=	MkL5V2FPT0WU
COR-L279	NGHlSW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnSwTWM2OD1\|Nj6xPVgyKM7:TR?=	Mle4V2FPT0WU
ATN-1	MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PrT2lEPTB;M{[uPFUyPiEQvF2=	M3jNdnNCVkeHUh?=
HCC2998	NGPydo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHhTWM2OD1\|Nj64OVcyKM7:TR?=	NV7xSXA{W0GQR1XS
UM-UC-3	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTN4Lki2O\|Uh\|ryP	MlriV2FPT0WU
DV-90	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnviTWM2OD1\|Nj65NFY4KM7:TR?=	M37TfHNCVkeHUh?=
ES8	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojrTWM2OD1\|Nj65N\|E5KM7:TR?=	NVf1OYIzW0GQR1XS
YAPC	NWfiZZJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfVO29HUUN3ME2zOk46PjV2IN88US=>	NYjPbnJpW0GQR1XS
HCC1599	M4ixNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3y2NmlEPTB;M{euNVYyQCEQvF2=	M4ix[XNCVkeHUh?=
UMC-11	NGG4WGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml60TWM2OD1\|Nz6yOVA{KM7:TR?=	MoTVV2FPT0WU
THP-1	NYLsNIk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjDOIV[UUN3ME2zO{4zQDZ6IN88US=>	NYDBZYdqW0GQR1XS
OCUB-M	MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLJdoVDUUN3ME2zO{4zQDlzIN88US=>	NUnydohkW0GQR1XS
NCI-H1693	NHfGc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXjTWM2OD1\|Nz6zNlM{KM7:TR?=	MoLkV2FPT0WU
NCI-H345	NE\T[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;oRmlbUUN3ME2zO{4{PjJ2IN88US=>	NX7OSY91W0GQR1XS
COLO-800	M1rWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{S0W2lEPTB;M{euOVY4KM7:TR?=	MnvLV2FPT0WU
COLO-320-HSR	NVnCN2tbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTN6LkO0PVIh\|ryP	NHPWd5VUSU6JRWK=
NCI-H596	NYXqXlhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTpZ21KSzVyPUO4MlQ1QDlizszN	NYPiR\|hWW0GQR1XS
NCI-H187	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTN6LkezOFQh\|ryP	NIrRWJdUSU6JRWK=
ECC4	NXG0N2g{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{SySmlEPTB;M{muNFgyPCEQvF2=	MnLTV2FPT0WU
KP-4	NGPobZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33TNmlEPTB;M{muNVI{PSEQvF2=	NULvWm55W0GQR1XS
NCI-H2227	NYj6TIk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTReohKSzVyPUO5MlM6PDlizszN	NHX2SoFUSU6JRWK=
22RV1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\QOmlEPTB;M{muPFM6QCEQvF2=	NV6wXmtiW0GQR1XS
SAS	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTTNXhKSzVyPUSwMlA6PiEQvF2=	NULTUG9qW0GQR1XS
PANC-10-05	M3nHV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfX[mExUUN3ME20NE4yQDJ6IN88US=>	MlzpV2FPT0WU
MDA-MB-468	NXLD[5hwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zxTmlEPTB;NECuOVM1PiEQvF2=	MlHIV2FPT0WU
RPMI-7951	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jNVWlEPTB;NEGuNlA4PSEQvF2=	NUTwW4k4W0GQR1XS
BB49-HNC	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWqwZol6UUN3ME20NU4zOTd7IN88US=>	M3vjTHNCVkeHUh?=
23132-87	NGrqZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkGzTWM2OD12MT6yO\|MzKM7:TR?=	Ml3OV2FPT0WU
HCC1569	NVLSVnpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jldWlEPTB;NEGuNlg5PSEQvF2=	M1TicXNCVkeHUh?=
CP66-MEL	NVnRb2ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYixXJVXUUN3ME20Nk4yQDh4IN88US=>	NVXzNHZwW0GQR1XS
K-562	NGX4TnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonmTWM2OD12Mj6yPFU1KM7:TR?=	NIjLTYtUSU6JRWK=
OCI-AML2	M3jWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLX[Y46UUN3ME20Nk45QTd2IN88US=>	MVrTRW5ITVJ?
SW756	Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTR\|LkCzPFgh\|ryP	NGrlUHBUSU6JRWK=
M14	MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTrPXJCUUN3ME20N{4{OTh7IN88US=>	MWHTRW5ITVJ?
NCI-H1623	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWSwVIR6UUN3ME20N{41PjRizszN	NW[y[WtbW0GQR1XS
KNS-81-FD	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPSTWM2OD12Mz63OlIh\|ryP	M3zWPXNCVkeHUh?=
TGBC1TKB	MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLC[IdKSzVyPUSzMlkxQTlizszN	MlPHV2FPT0WU
RERF-LC-MS	M{jqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPMTWM2OD12Mz65NlgyKM7:TR?=	M3rLTXNCVkeHUh?=
PC-3	M1XtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjhSGhKSzVyPUS0MlQ{PDdizszN	NVv1RWFXW0GQR1XS
HuP-T4	NEf0SI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rzV2lEPTB;NESuOFQ4PCEQvF2=	Mki4V2FPT0WU
NCI-H510A	M320[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYf0WVBYUUN3ME20OE44ODhizszN	MVTTRW5ITVJ?
LB2518-MEL	MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPMTWM2OD12ND63PVM4KM7:TR?=	NYf6SZd1W0GQR1XS
TE-5	NX\vSodqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVi3UJd1UUN3ME20OU46PThzIN88US=>	M2XoOHNCVkeHUh?=
EW-24	M1zmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTR4LkG3NlMh\|ryP	NVnNV5U3W0GQR1XS
LB647-SCLC	MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HBNmlEPTB;NE[uNlE2PSEQvF2=	M{n2OHNCVkeHUh?=
NCI-H524	NYC1V5pzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvFTWM2OD12Nj63NVg2KM7:TR?=	MX7TRW5ITVJ?
EW-11	M{LQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHmxSopKSzVyPUS2Mlk{PzNizszN	M{jmfHNCVkeHUh?=
KALS-1	MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTR5LkKwOlYh\|ryP	NVnxWllXW0GQR1XS
BT-474	NH\EemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTR5LkSyNVYh\|ryP	M4LxO3NCVkeHUh?=
SK-N-AS	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTvTWM2OD12Nz64PFgh\|ryP	NW\wOJdMW0GQR1XS
HCC2157	M3fKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlK3TWM2OD12OD6wO\|Yh\|ryP	MVvTRW5ITVJ?
HCC1954	M3;EXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDEVJBVUUN3ME20PE4yPzB2IN88US=>	M3vxZ3NCVkeHUh?=
FADU	M2nXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDRTJgxUUN3ME20PE4{ODNzIN88US=>	MkC3V2FPT0WU
S-117	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnmfoJMUUN3ME20PE4{QDF3IN88US=>	NGiw[GFUSU6JRWK=
LS-1034	NIXRWm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2OwXGlEPTB;NEiuO\|A3PyEQvF2=	NILPcoFUSU6JRWK=
CAMA-1	NGDtOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHj2[\|RKSzVyPUS5MlU2PDNizszN	NFf2SW9USU6JRWK=
LU-134-A	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnWVZJKSzVyPUS5MlgxQDVizszN	M3TRZ3NCVkeHUh?=
NCI-H1838	M1;lZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTR7LkiwPFch\|ryP	MkL2V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pSrc / Src / pPlcg / Plcg / pStat5 / Stat5 ; PubMed: 22781593 Leukemia In (B) inhibition of Src, Plcg and Stat5 was seen in MLNAF cell lines treated with Ponatinib; ZNF112 expresses ZMYM2–FGFR1, CEP2A and CEP5A cells express CEP110–FGFR1 and BBC2 expresses BCR–FGFR1. pFGFR1(pY20) / FGFR1; PubMed: 22781593 Leukemia Western blot analysis, using various antibodies specific for downstream targets of FGFR1, demonstrates that Ponatinib inhibits the activation of Plcg and Src as a result of inhibiting the FGFR1 fusion kinase in human KG1 cells. cleaved caspase-3 / cleaved caspase-7 / BAX / Bcl-2; PubMed: 30959969 Molecules Western blot analysis of cleaved caspase-3, cleaved caspase-7, Bax, Bcl-2, and β-Tubulin (control) in treated cells. p-Rb(S807/811) / Rb / CDK4 / CDK6 / Cyclin D1 / CDK2 / Cyclin E1; PubMed: 30959969 Molecules Western blot analysis of Rb/p-Rb, CDK4, CDK6, Cyclin D1, CDK2, Cyclin E1, and β-Tubulin (control) in the SK-Hep-1 and SNU-423 cells treated with ponatinib. RAD51; PubMed: 30959969 Molecules The effect of ponatinib on the concentration of Rad51 in SK-Hep-1 and SNU-423 cells. p-MEK / MEK / p-ERK / ERK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Mek and Erk. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. c-Jun / p-JNK(T183/Y185) / JNK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of JNK and c-Jun. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-p38 MAPK / p38 MAPK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of p38. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-JAK2 / JAK2 / p-STAT3 / STAT3; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Jak2, and Stat3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. PI3K p85 / p-PI3K / p-PDK1 / PDK1 / p-mTOR / mTOR; PubMed: 30959969 Molecules Effects of ponatinib on the protein concentration and phosphorylation of PI 3-kinase, PDK1, Akt, and mTOR in HCC cells. p-PDGFRα / PDGFRα; PubMed: 24472312 Mol Cancer Ponatinib inhibited phosphorylation of PDGFRα in a concentration-dependent manner. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to escalating concentrations of ponatinib for 24 h. PARP / Caspase-3 / Active Caspase-3; PubMed: 24472312 Mol Cancer The concentration- (for 24 h) and time-dependent (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells) cleavage of PARP and caspase-3 triggered by ponatinib was analyzed by immunoblotting. AIF / Cyto C ; PubMed: 24472312 Mol Cancer Ponatinib elicited release of AIF and cytochrome c into the cytosol. Cells were treated with 1 nM ponatinib for the indicated durations and the cytosolic fraction was extracted with digitonin buffer. Levels of AIF and Cytochrome c (Cyto c) were detected by immunoblotting. Mcl-1 / Survivin / Bcl-Xl / XIAP / Bax / Bcl-2 / Bim; PubMed: 24472312 Mol Cancer Immunoblotting of apoptosis-related proteins in CEL cells after treatment for 24 h. β-catenin ; PubMed: 24472312 Mol Cancer Ponatinib concentration-dependently lowered β-catenin. EOL-1 cells were incubated with ponatinib for 24 h, and cytoplasmic and nuclear extracts were determined by immunoblotting. β-catenin; PubMed: 24472312 Mol Cancer Analysis of β-catenin localization. EOL-1 cells were pretreated with 1 nM ponatinib for 24 h, immunofluorescence analysis was performed with anti-β-catenin. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). ABL; PubMed: 19878872 Cancer Cell In vitro [γ-32P]-ATP autophosphorylation of full-length (A) ABL or (B) ABLT315I kinase treated with AP24534, imatinib, nilotinib, or dasatinib. After incubation of tyrosine-dephosphorylated enzyme with the indicated inhibitor in the presence of [γ-32P]-ATP and separation by SDS-PAGE, signal intensity was measured by autoradiography.	22781593 30959969 24472312 19878872
Growth inhibition assay	Cell viability; PubMed: 30174789 Oncotarget (A) Effect of Ponatinib on basal viability of HUVECs. The cells were treated with Ponatinib at indicated concentrations or 0.1% DMSO (vehicle control) for 24 h.	30174789

In vivo

In a mouse xenograft model of Ba/F3 cells expressing native Bcr-Abl, AP24534 (2.5 mg/kg and 5 mg/kg) prolongs mice median survival. In the xenograft model of Ba/F3 Bcr-Abl^T315I, AP24534 (10 mg/kg–50 mg/kg) significantly suppresses tumor growth. AP24534 (30 mg/kg) decreases the phosphorylated Bcr-Abl and phosphorylated CrkL levels in the tumors. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand Peptide substrate phosphorylation assays with GST-Abl kinase domains: The effect of AP24534 (0-320 nM) on GST-Abl kinase activity is assessed by using a synthetic peptide substrate (Abltide: EAIYAAPFAKKK). Assays are carried out at 30 °C for 15 min in 25 μL reaction mixture: 8 mM MOPS (pH 7), 0.2 mM EDTA, 50 μM Abltide, 30 mM MgCl₂, 10 mM β-glycerol phosphate, 1 mM EGTA, 0.002% Brij-35, 0.4 mM DTT, 0.2 mg/mL BSA, 0.4 mM sodium orthovanadate, 10 nM WT or mutant GST-Abl kinase, and 100 µM ATP/γ-³²[P]ATP (5000 cpm/pmol). Reactions are terminated by transferring a portion of the reaction mixture onto a p81 phosphocellulose filter and immersing in 0.75% phosphoric acid. Filters are washed 3 times in 0.75% phosphoric acid, rinsed in acetone, and air dried; phosphate incorporation is determined by scintillation counting. All results are corrected for background binding to the filters, as determined by omitting peptide substrate from the kinase reaction. Time course experiments to establish the linear range of enzymatic activity precedes kinase assays.
Cell Research:^[2]	+ Expand Cell lines: Ba/F3 cells expressing Bcr-Abl or a range of single mutations in the kinase domain of Bcr-Abl Concentrations: 0-625 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are distributed in 96-well plates (4 × 10³ cells/well) and incubated with AP24534 for 72 hours. Proliferation is measured using a methanethiosulfonate (MTS)-based viability assay (CellTiter96 Aqueous One Solution). All values are normalized to the control wells with no drug. IC50 values are reported as the mean of three independent experiments performed in quadruplicat (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Mouse xenograft models of Ba/F3 cells expressing Bcr-Abl or Bcr-Abl^T315I Formulation: Dissolved in 25 mM citrate buffer, pH 2.75 Dosages: 2.5 mg/kg and 5 mg/kg for Ba/F3 Bcr-Abl; 2.5 mg/kg–50 mg/kg for Ba/F3 Bcr-Abl^T315I Administration: Oral gavage once daily (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	30 mg/mL (56.33 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ponatinib (AP24534) SDF

Molecular Weight	532.56
Formula	C₂₉H₂₇F₃N₆O
CAS No.	943319-70-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04070443	Not yet recruiting	Drug: Ponatinib\|Drug: Imatinib	Philadelphia Chromosome Positive CML\|BCR-ABL Positive Chronic Myelogenous Leukemia	Centre Leon Berard	October 1 2019	Phase 2
NCT03934372	Not yet recruiting	Drug: Ponatinib	Acute Myeloid Leukemia\|Accelerated Phase Chronic Myeloid Leukemia\|Blast Phase Chronic Myeloid Leukemia\|Chronic Phase Chronic Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphocytic Leukemia\|Leukemia\|Lymphoma\|Solid Tumors	Incyte Biosciences International Sàrl\|Incyte Corporation	October 25 2019	Phase 1\|Phase 2
NCT03895671	Recruiting	Drug: Ponatinib\|Drug: Azacitidine	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE\|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS	Versailles Hospital	June 19 2019	Phase 2
NCT03690115	Recruiting	Drug: Ponatinib 30 MG	Leukemia Myeloid Acute	Versailles Hospital	December 12 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is the pre-solubilized inhibitor suitable for in vivo whole animal studies? Whether the solvent contains any non-DMSO stabilizer?
Answer:
Our 10mM Ponatinib in DMSO solution is in pure DMSO and there is not other stabilizer added. You can use it for animal study. The vehicle we suggest for Ponatinib is: 30% PEG400/0.5% Tween80/5% Propylene glycol. It is a milky suspension used for oral gavage.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Selective Bcr-Abl Inhibitor

Nilotinib (AMN-107) : Bcr-Abl-selective, IC50<30 nM.
Most Potent Bcr-Abl Inhibitor

GZD824 : Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.
FDA-approved Bcr-Abl Inhibitor

Dasatinib : Approved by FDA for CML and Ph+ ALL.
Newest Bcr-Abl Inhibitor

GZD824 : Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

Related Bcr-Abl Products

PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.
Defactinib (VS-6063, PF-04554878) ^New

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
Imatinib Mesylate (STI571)

Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.
Nilotinib (AMN-107)

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

Features:A selective inhibitor of native and mutant Bcr-Abl.
Bafetinib (INNO-406)

Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Phase 2.

Features:Dual Bcr-Abl/Lyn inhibitor.
Degrasyn (WP1130)

Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).

Features:WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.
Rebastinib (DCC-2036)

Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.

Features:A conformational control inhibitor of Abl1 and T315I Abl1.
GZD824 Dimesylate(HQP1351)

GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
GNF-2

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.

Choose Your Country or Region

By Signaling Pathways

By product type

Ponatinib (AP24534)

Cited by 51 Publications

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ponatinib (AP24534) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Related Bcr-Abl Products

Choose Your Country or Region

By Signaling Pathways

By product type

Ponatinib (AP24534)

Cited by 51 Publications

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ponatinib (AP24534) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Related Bcr-Abl Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)